Immune biomarker evaluation of sequential tyrosine kinase inhibitor and nivolumab monotherapies in renal cell carcinoma: the phase I TRIBE trial по K.S. Shohdy, M. Pillai, K.S. Abbas, J. Allison, T. Waddell, E. Darlington, S. Mohammad, S. Hood, S. Atkinson, K. Simpson, D. Morgan, P. Nathan, E. Kilgour, C. Dive, F. Thistlethwaite

Полный текст